Phase II Trial Of Medium-Dose VP-16, Cyclophosphamide and Total-Body Irradiation Conditioning Regimen Before Allogeneic Stem Cell Transplantation For Acute Lymphoblastic Leukemia In Adults

被引：0
|
作者：
Goto, Tatsunori
Shigematsu, Akio
Onizuka, Makoto
Fujisawa, Shin
Suzuki, Ritsuro
Atsuta, Yoshiko
Hatanaka, Kazuo
Masuko, Masayoshi
Ito, Toshiro
Kobayashi, Naoki
Kato, Jun
Miyamura, Koichi
Fukuda, Takahiro
Morishima, Yasuo
Imamura, Masahiro
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.544.544
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
544
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase I-II study of cyclophosphamide (CY), VP-16, carboplatin (CBDCA), and total body irradiation (TBI) with autologous stem cell transplantation for acute leukemia.
    Wiley, J
    Shea, T
    Powell, E
    Serody, J
    Gabriel, D
    Sailer, S
    Killian, D
    Bentley, S
    Brecher, M
    BLOOD, 1996, 88 (10) : 3702 - 3702
  • [22] TOTAL-BODY IRRADIATION AND MAXIMUM DOSE VP 16 FOLLOWED BY ALLOGENEIC BONE-MARROW TRANSPLANTATION IN LYMPHOBLASTIC-LEUKEMIA AND LYMPHOMA
    SCHMITZ, N
    GASSMANN, W
    RISTER, M
    SUTTORP, M
    LOFFLER, H
    BLUT, 1988, 57 (04): : 214 - 214
  • [23] HIGH-DOSE CYCLOPHOSPHAMIDE, BCNU, AND VP-16 (CBV) AS A CONDITIONING REGIMEN FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE-LEUKEMIA
    ZANDER, AR
    CULBERT, S
    JAGANNATH, S
    SPITZER, G
    KEATING, M
    LARRY, N
    COCKERILL, K
    HESTER, J
    HORWITZ, L
    VELLEKOOP, L
    SWAN, F
    MCCREDIE, K
    DICKE, KA
    CANCER, 1987, 59 (06) : 1083 - 1086
  • [24] Pharmacokinetics of high-dose etoposide administered in combination with fractionated total-body irradiation as conditioning for allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia
    Chrzanowska, Maria
    Sobiak, Joanna
    Grund, Grzegorz
    Wachowiak, Jacek
    PEDIATRIC TRANSPLANTATION, 2011, 15 (01) : 96 - 102
  • [25] Clofarabine and Total Body Irradiation as a Conditioning Regimen for Allogeneic Stem Cell Transplantation in High-Risk Acute Leukemia
    Atoui, Ali
    Dulery, Remy
    Terro, Khodr
    Abou Dalle, Iman
    Bazarbachi, Ali
    Mohty, Mohamad
    El Cheikh, Jean
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S432 - S432
  • [26] Busulfan and cyclophosphamide (Bu/Cy) with and without VP-16 for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia (ALL).
    Absi, A
    Bolwell, BJ
    Sobecks, R
    Pohlman, B
    Andresen, S
    Rybicki, L
    Kalaycio, M
    BLOOD, 2003, 102 (11) : 466B - 467B
  • [27] TOTAL-BODY IRRADIATION AND HIGH-DOSE CYCLOPHOSPHAMIDE, BCNU AND VP-16 (CBV) AS A NEW PREPARATORY REGIMEN FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES
    WU, DP
    MILPIED, N
    MOREAU, P
    MECHINAUDLACROIX, F
    MAHE, B
    LETORTOREC, S
    RAPP, MJ
    BOURDIN, S
    MAHE, JM
    HAROUSSEAU, JL
    BONE MARROW TRANSPLANTATION, 1994, 14 (05) : 751 - 757
  • [28] FRACTIONATED TOTAL-BODY IRRADIATION (FTBI) PLUS HIGH-DOSE VP-16 BEFORE ALLOGENEIC BONE-MARROW TRANSPLANTATION IN ADVANCED LEUKEMIA - CLINICAL AND PHARMACOKINETIC EVALUATION
    SCHMITZ, N
    HOLTHUIS, JJM
    GASSMANN, W
    KAYSER, W
    RISTER, M
    LOFFLER, H
    EXPERIMENTAL HEMATOLOGY, 1987, 15 (05) : 540 - 540
  • [29] Efficacy of High-Dose Cytarabine Added to Cyclophosphamide/Total-Body Irradiation in the Conditioning Regimen of Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancy
    Arai, Yasuyuki
    Aoki, Kazunari
    Takeda, June
    Kondo, Tadakazu
    Eto, Tetsuya
    Ota, Shuichi
    Hashimoto, Hisako
    Fukuda, Takahiro
    Ozawa, Yukiyasu
    Kanda, Yoshinobu
    Kato, Chiaki
    Kurokawa, Mineo
    Iwato, Koji
    Onizuka, Makoto
    Ichinohe, Tatsuo
    Atsuta, Yoshiko
    Takami, Akiyoshi
    BLOOD, 2015, 126 (23)
  • [30] Medium-dose etoposide, cyclophosphamide and total body irradiation conditioning potentiates anti-leukemia immunity in adults with acute lymphoblastic leukemia without aggravating graft-versus-host disease
    Imamura, Masahiro
    CYTOTHERAPY, 2023, 25 (12) : 1251 - 1258
12345